MedPath

Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment

Completed
Conditions
Non-small Cell Lung Cancer
Metastatic Cancer
Lung Cancer
Brain and Central Nervous System Cancer
Registration Number
NCT06557967
Lead Sponsor
Daiichi Sankyo
Brief Summary

This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.

Detailed Description

This retrospective cohort database study will generate real-world evidence describing prevalence of brain metastases at metastatic diagnosis and by line of therapy, patient characteristics, treatment patterns, and clinical outcomes in metastatic non-small cell lung cancer (mNSCLC) patients

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22517
Inclusion Criteria
  1. Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC

  2. Age 18+ years at the time of diagnosis of mNSCLC

    Additional inclusion criteria for 1st Line of Therapy cohort:

  3. Treated with systemic anti-cancer therapy in 1L setting

    Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts:

  4. Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting

Exclusion Criteria
  1. Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period
  2. Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall Survival (OS) of (AGA+/-) mNSCLC Participant With And Without Brain Metastases by Line of TherapyFrom baseline to end of follow-up or death, whichever comes first, up to approximately 40 months.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

ConcertAI Database

🇺🇸

Cambridge, Massachusetts, United States

ConcertAI Database
🇺🇸Cambridge, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.